Press Releases
Articles in this section
-
#FreeChangsha3: Wrongfully Detained HIV/Viral Hepatitis Activists
Three Chinese lawyers and advocates, Cheng Yuan, Wu Gejianxiong, and Liu Yongze, who work on employment discrimination and disability justice for people living with HIV and viral hepatitis, have been wrongfully detained in Hunan, China since 22 July 2019. More
-
Hepatitis C cure, sofosbuvir, turns 5 years old: The vast majority of people still have not been treated
Advocates scandalized that Gilead’s hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billion in profits.
6 December 2018, Paris, France, New York, NY— People living with hepatitis C, access to medicines activists, and the medical (...) More -
APN+ joins MTAAG+ in congratulating Malaysia on sofosbuvir compulsory license CL ends Gilead’s dangerous games with lives of HepC patients in Malaysia Result of hard fought efforts of community-based groups, NGOs and treatment providers
20 September 2017, Bangkok and Kuala Lumpur: The Asia-Pacific Network of People living with HIV (APN+) joins the Positive Malaysian Treatment Access and Advocacy Group (MTAAG+) in welcoming the approval of a government use license (also known as compulsory license or CL) in Malaysia for (...) More
-
Hepatitis C: Gilead patent on sofosbuvir partially maintained following MdM patent opposition Paris, October 5th 2016
European Patent Office (EPO) has taken its decision following Doctors of the World - Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
MdM has filled an opposition on the patent granted to Gilead Sciences for (...) More -
Hepatitis C: no more treatment rationing; universal access to generic medicines everywhere! 16 April 2016
Find below some pictures of the demonstration as well as videos in english and in spanish
Barcelona – People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV (...) More